Table 1. . Summary of current response criteria.
| Criterion | RECIST | MacDonald | RANO |
|---|---|---|---|
| Measurement | 1D contrast enhancement | 2D contrast enhancement | 2D contrast enhancement + T2/FLAIR |
| Progression | ≥20% increase in sum of lesions | ≥25% increase in product of perpendicular diameter | ≥25% increase in product of perpendicular diameter |
| Response | ≥30% decrease in sum of lesions | ≥50% decrease in product of perpendicular diameter | ≥50% decrease in product of perpendicular diameter |
| Durability of response | Optional | Yes (at least 4 week) | Yes (at least 4 week) |
| Definition of measurability | Yes | No | Yes |
| Number of target lesions | Up to 5 | None specified | Up to 5 |
| T2/FLAIR | Not evaluated | Not evaluated | Evaluated |
| Corticosteroids considered | No | Yes | Yes |
| Clinical status considered | No | Yes | Yes |
| Pseudo-progression considered | No | No | Yes |
RANO: Response Assessment in Neuro-Oncology; RECIST: Response Evaluation Criteria in Solid Tumors.